Technology

Kanyr Pharma has identified a key protein tyrosine phosphatase (PTP) that negatively regulates immune cell activation. We have developed proprietary small-molecule inhibitors targeting this PTP and demonstrated their ability to enhance immune cell activity against cancer cells. Our lead compounds are designed for oral administration, offering the potential for a convenient and effective immunotherapy approach. 

Immunyr™ is an ex vivo dendritic cell–based platform that uses proprietary protein tyrosine phosphatase (PTP) inhibitors to enhance the development of therapeutic cancer vaccines. By modulating dendritic cell function, Immunyr™ increases their ability to prime robust anti-tumor immune responses. When combined with tumor-specific antigens, this approach enables the development of personalized cancer vaccines. 

 Kanyr is developing a proprietary small-molecule lead compound targeting PRL (phosphatase of regenerating liver) phosphatases. PRLs are among the most oncogenic members of the PTP family and are frequently overexpressed in a wide range of cancers. They are implicated in promoting tumor cell proliferation, invasion, and metastasis across many tumor types.